Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a open-label single-center placebo-controlled study of cannabidiol as a steroid-sparing treatment in chronic spontaneous urticaria
MOH_2020-01-14_008624Phase 2Not yet recruiting
- Sponsor
- STERO Biotechs
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cannabidiol in chronic idiopathic urticaria (CIU), sponsored by STERO Biotechs. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on MOH_2020-01-14_008624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-01-14_008624.